2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

101. Red Cells and Erythropoiesis, Excluding Iron: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Treatment Considerations, Supportive Care, Biological Therapies, Antibody Therapy, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Biological Processes, Apoptosis, Pathogenesis, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality of Care, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Neonatal
PAPER

2859 Genetic and chemical tools for temporal dissection of integrator function during human erythropoiesis

Alexander Parks, BS, Deanna M Abid2, KaiLeih Huang3, Eric Wagner4, Laurie A Steiner, MD5
1 University of Rochester, Rochester, New York, United States
2 University of Rochester, Rochester, New York, United States
3 University of Rochester, Rochester, New York, United States
4 University of Rochester, Rochester, New York, United States
5 University of Rochester, Rochester, New York, United States

Promoter-proximal pausing of RNA polymerase II (RNAPII) is a critical transcriptional checkpoint that determines whether transcription proceeds into productive elongation or terminates prematurely at the promoter proximal region. During terminal erythroid maturation, global RNAPII abundance progressively declines despite continued high-level expression of erythroid genes, suggesting that efficient recycling of paused RNAPII becomes increasingly important. The Integrator complex promotes promoter-proximal transcription termination and RNAPII recycling through coordinated phosphatase and endonuclease activities. Consistent with an essential role in erythropoiesis, Integrator occupancy at promoter regions increases during terminal maturation, and partial depletion of the essential scaffold subunit Integrator subunit 1 (INTS1) impairs erythroid differentiation and reduces β-globin (HBB) expression. However, mechanistic studies have been limited by the lack of approaches that permit acute, stage-specific inhibition of Integrator activity.

            To overcome this limitation, we developed complementary genetic and pharmacologic platforms for temporal control of Integrator activity. First, we engineered an endogenous dTAG degron strategy in HUDEP-2 cells to enable rapid, inducible degradation of INTS1. Because precise genome editing in HUDEP-2 cells is inefficient, we incorporated a self-cleaving P2A-GFP cassette into the knock-in design, allowing flow cytometric enrichment of rare, edited cells while preserving endogenous INTS1 regulation. This platform enables acute depletion of INTS1 at defined stages of erythroid differentiation, providing a powerful approach to distinguish direct transcriptional effects from secondary consequences of chronic Integrator loss.

            To extend temporal perturbation to genetically intractable systems, including primary CD34+ erythroid cultures and in vivo models, we developed an orthogonal high-throughput chemical screening platform based on Integrator-dependent processing of small nuclear RNAs (snRNAs). In this platform, an engineered reporter places GFP downstream of an artificial snRNA transcription unit, such that inhibition of Integrator endonuclease activity results in RNAPII readthrough and GFP expression. Using this system, we screened approximately 14,000 small molecules, identified nine primary hits, and validated one lead compound that phenocopies loss of Integrator endonuclease function. The validated compound induces RNAPII readthrough at endogenous snRNA loci, derepresses canonical Integrator-regulated noncoding and protein-coding transcripts, and demonstrates dose-dependent activity suitable for structure-activity relationship optimization.

            Together, these complementary genetic and chemical tools establish the first platform for acute, stage-specific manipulation of Integrator activity during erythropoiesis. These approaches will enable mechanistic dissection of promoter-proximal transcription termination and RNAPII recycling during erythroid maturation while providing broadly applicable tools to investigate Integrator biology in primary cells and in vivo.

Alexander Parks, BS: No relevant conflicts of interest to declare.